- Last edited on June 7, 2026
Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision | |||
|
meds:antipsychotics:eps [on June 3, 2025] psychdb [Resources] |
meds:antipsychotics:eps [on June 7, 2026] (current) psychdb |
||
|---|---|---|---|
| Line 111: | Line 111: | ||
| * Other treatments include [[meds:non-benzo-anxiolytics:propranolol|propranolol]] or [[meds:antidepressants:nassa:mirtazapine|mirtazapine]].[([[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4622124/|Praharaj, S. K., Kongasseri, S., Behere, R. V., & Sharma, P. S. V. N. (2015). Mirtazapine for antipsychotic-induced acute akathisia: a systematic review and meta-analysis of randomized placebo-controlled trials. Therapeutic advances in psychopharmacology, 5(5), 307-313.]])][([[https://www.ncbi.nlm.nih.gov/pubmed/20118449|Poyurovsky, M. (2010). Acute antipsychotic-induced akathisia revisited.]])][([[https://www.ncbi.nlm.nih.gov/pubmed/18460588|Hieber, R., Dellenbaugh, T., & Nelson, L. A. (2008). Role of mirtazapine in the treatment of antipsychotic-induced akathisia. Annals of Pharmacotherapy, 42(6), 841-846.]])] | * Other treatments include [[meds:non-benzo-anxiolytics:propranolol|propranolol]] or [[meds:antidepressants:nassa:mirtazapine|mirtazapine]].[([[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4622124/|Praharaj, S. K., Kongasseri, S., Behere, R. V., & Sharma, P. S. V. N. (2015). Mirtazapine for antipsychotic-induced acute akathisia: a systematic review and meta-analysis of randomized placebo-controlled trials. Therapeutic advances in psychopharmacology, 5(5), 307-313.]])][([[https://www.ncbi.nlm.nih.gov/pubmed/20118449|Poyurovsky, M. (2010). Acute antipsychotic-induced akathisia revisited.]])][([[https://www.ncbi.nlm.nih.gov/pubmed/18460588|Hieber, R., Dellenbaugh, T., & Nelson, L. A. (2008). Role of mirtazapine in the treatment of antipsychotic-induced akathisia. Annals of Pharmacotherapy, 42(6), 841-846.]])] | ||
| * The use of anticholinergic medications such as benztropine should not be routinely used due to poor evidence and risk of side effects.[([[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299189/|Pringsheim, T., Gardner, D., Addington, D., Martino, D., Morgante, F., Ricciardi, L., ... & Barnes, T. R. (2018). The assessment and treatment of antipsychotic-induced akathisia. The Canadian Journal of Psychiatry, 63(11), 719-729.]])] | * The use of anticholinergic medications such as benztropine should not be routinely used due to poor evidence and risk of side effects.[([[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299189/|Pringsheim, T., Gardner, D., Addington, D., Martino, D., Morgante, F., Ricciardi, L., ... & Barnes, T. R. (2018). The assessment and treatment of antipsychotic-induced akathisia. The Canadian Journal of Psychiatry, 63(11), 719-729.]])] | ||
| - | * There is also limited evidence that Vitamin D6 can be used in persistent akathisia.[([[https://www.ncbi.nlm.nih.gov/pubmed/15554771/|Lerner, V., Bergman, J., Statsenko, N., & Miodownik, C. (2004). Vitamin B6 treatment in acute neuroleptic-induced akathisia: a randomized, double-blind, placebo-controlled study. The Journal of clinical psychiatry, 65(11), 1550-1554.]])] | + | * There is also limited evidence that Vitamin B6 can be used in persistent akathisia.[([[https://www.ncbi.nlm.nih.gov/pubmed/15554771/|Lerner, V., Bergman, J., Statsenko, N., & Miodownik, C. (2004). Vitamin B6 treatment in acute neuroleptic-induced akathisia: a randomized, double-blind, placebo-controlled study. The Journal of clinical psychiatry, 65(11), 1550-1554.]])] |
| <panel type="info" title="Treatment for Akathisia" no-body="true"> | <panel type="info" title="Treatment for Akathisia" no-body="true"> | ||